Boston Scientific (BSX) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $44.91 -0.86%
EPS Growth %: +10.7%
Financial Fact:
Net income (loss) per common share - assuming dilution: 0.17
Today's EPS Names:
CRMT, PKE, HELE, More
EPS Growth %: +10.7%
Financial Fact:
Net income (loss) per common share - assuming dilution: 0.17
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.80, $0.02 better than the analyst estimate of $0.78. Revenue for the quarter came in at $5.29 billion versus the consensus estimate of $5.28 billion.
GUIDANCE:
Boston Scientific sees FY2026 EPS of $3.43-$3.49, versus the consensus of $3.47.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lyft to acquire Serveo's bikeshare business in Spain
- Keurig Dr Pepper (KDP) PT Raised to $39 at Bernstein SocGen Group
- Performance Shipping amends Nordea loan, cutting margin to 1.60%
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
